Jefferies upgrades Moderna, citing optimism around promising experimental cancer vaccine
The biotech stock is down more than 23% in 2022, compared to the S&P 500's 19% decline.
LocalNews
0
20
The biotech stock is down more than 23% in 2022, compared to the S&P 500's 19% decline.
